WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2009060226) INTRANASAL COMPOSITIONS
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2009/060226    International Application No.:    PCT/GB2008/003782
Publication Date: 14.05.2009 International Filing Date: 10.11.2008
IPC:
A61K 9/00 (2006.01), A61K 47/26 (2006.01), A61K 47/34 (2006.01), A61K 47/40 (2006.01), A61K 31/473 (2006.01)
Applicants: ARCHIMEDES DEVELOPMENT LIMITED [GB/GB]; Albert Einstein Centre, Nottingham Science & Technology Park, University Boulevard, Nottingham NG7 2TN (GB) (For All Designated States Except US).
WATTS, Peter [GB/GB]; (GB) (For US Only).
CHENG, Yu-Hui [CN/GB]; (GB) (For US Only)
Inventors: WATTS, Peter; (GB).
CHENG, Yu-Hui; (GB)
Agent: CROWHURST, Charlotte; Potter Clarkson LLP, Park View House, 58 The Ropewalk, Nottingham NG1 5DD (GB)
Priority Data:
07254426.5 09.11.2007 EP
Title (EN) INTRANASAL COMPOSITIONS
(FR) COMPOSITIONS INTRANASALES
Abstract: front page image
(EN)The present invention provides a liquid aqueous formulation for the intranasal administration of apomorphine, which comprises: (a) at least about 15 mg/ml of apomorphine; and (b) a solubilising agent selected from (i) at least one polyoxyethylene-polyoxypropylene copolymer (poloxamer); (ii) at least one cyclodextrin; and (iii) at least one cyclodextrin together with chitosan. The formulations of the invention can be used in the treatment/management of Parkinson's disease.
(FR)La présente invention concerne une formulation aqueuse liquide destinée à l'administration intranasale d'apomorphine et comprenant : (a) au moins 15 mg/ml environ d'apomorphine; et (b) un agent de solubilisation choisi parmi (i) au moins un copolymère de polyoxyéthylène et polyoxypropylène (poloxamère); (ii) au moins une cyclodextrine; et (iii) au moins une cyclodextrine combinée avec du chitosane. Les formulations de l'invention peuvent être utilisées dans le traitement/la prise en charge de la maladie de Parkinson.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)